Chester County News and Community Website
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported that enrollment in its pivotal Phase 3 Alzheimer’s disease trial has reached 85% and remains on track for completion this summer, …
Annovis Nears Full AD Enrollment Ahead of NDA Plans Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) presented new Phase 2 data showing statistically significant reductions in lesion bleeding among patients treated with QTORIN rapamycin for cutaneous venous malformations, …
Palvella Advances Rare Disease Program With Phase 2 Data Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported expanded Phase 2 data for its SkinJect skin cancer therapy and advanced development of its Teverelix prostate cancer program during the …
Medicus Advances Cancer Pipeline as Losses Widen Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported first-quarter financial results and outlined plans to advance its autoimmune disease cell therapy program toward potential regulatory filings, while expanding manufacturing …
Cabaletta Advances Pivotal Trials as Cash Runway Extends Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported early clinical data showing two of four autoimmune disease patients treated with its experimental CAR-T therapy remained drug-free for six months …
Cabaletta Reports Drug-Free Responses in CAR-T Study Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (Nasdaq: IPSC) said it remains on track to seek regulatory clearance next year for its experimental type 1 diabetes cell therapy as the company …
Century Advances Diabetes Cell Therapy Toward Human Trials Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) said it will expand enrollment in its lead cancer drug trial after closing an oversubscribed $30 million private placement, as early patient …
Aprea Expands Cancer Trial After $30 Million Financing Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) outlined a 2027 timeline for pivotal hypertension trial data and potential FDA submissions as the company and partner Medtronic advance …
Orchestra BioMed Advances FDA Path for Hypertension Device Read More WILMINGTON, DE — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) reported that it has secured regulatory clearance in 16 countries for its Phase 3 pulmonary arterial hypertension study, marking a key step …
Inhibikase Gains EU Clearance for Global PAH Trial Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) said it expects to complete enrollment in its pivotal BACKBEAT clinical trial by the end of the third quarter of …
Orchestra BioMed Targets 2027 Data for Hypertension Trial Read More